Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

Drugs that target the chief mediator of nuclear export, chromosome region maintenance 1 protein (CRM1) have potential as therapeutics for leukemia, but existing CRM1 inhibitors show variable potencies and a broad range of cytotoxic effects. Here, we report the structural analysis and antileukemic activity of a new generation of small-molecule inhibitors of CRM1. Designated selective inhibitors of nuclear export (SINE), these compounds were developed using molecular modeling to screen a small virtual library of compounds against the nuclear export signal (NES) groove of CRM1. The 2.2-Å crystal structure of the CRM1-Ran-RanBP1 complex bound to KPT-251, a representative molecule of this class of inhibitors, shows that the drug occupies part of the groove in CRM1 that is usually occupied by the NES, but penetrates much deeper into the groove and blocks CRM1-directed protein export. SINE inhibitors exhibit potent antileukemic activity, inducing apoptosis at nanomolar concentrations in a panel of 14 human acute myeloid leukemia (AML) cell lines representing different molecular subtypes of the disease. When administered orally to immunodeficient mice engrafted with human AML cells, KPT-251 had potent antileukemic activity with negligible toxicity to normal hematopoietic cells. Thus, KPT-SINE CRM1 antagonists represent a novel class of drugs that warrant further testing in AML patients.

[1]  Peter Washausen,et al.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. , 2009, Cancer research.

[2]  Yuh Min Chook,et al.  Recognition of nuclear targeting signals by Karyopherin-β proteins. , 2010, Current opinion in structural biology.

[3]  Yuh Min Chook,et al.  Structural basis for assembly and disassembly of the CRM1 nuclear export complex , 2009, Nature Structural &Molecular Biology.

[4]  Guido Marcucci,et al.  Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. , 2012, Blood.

[5]  Yuh Min Chook,et al.  Structural basis for leucine-rich nuclear export signal recognition by CRM1 , 2009, Nature.

[6]  Thomas Monecke,et al.  Crystal Structure of the Nuclear Export Receptor CRM1 in Complex with Snurportin1 and RanGTP , 2009, Science.

[7]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[8]  Donald W Kufe,et al.  CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. , 2011, Blood.

[9]  E. Newlands,et al.  Phase I trial of elactocin. , 1996, British Journal of Cancer.

[10]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[11]  A. Look,et al.  Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. , 2010, Blood.

[12]  G. Blobel,et al.  Structure of the nuclear transport complex karyopherin-beta2-Ran x GppNHp. , 1999, Nature.

[13]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[14]  Wim Dehaen,et al.  Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. , 2008, Bioorganic & medicinal chemistry.

[15]  Jay Painter,et al.  Electronic Reprint Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion , 2005 .

[16]  Michael Sattler,et al.  NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1 , 2010, Nature Structural &Molecular Biology.

[17]  M. Sormani,et al.  BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. , 2006, Blood.

[18]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[19]  N. Kudo,et al.  Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[21]  Ulrike Kutay,et al.  Leucine-rich nuclear-export signals: born to be weak. , 2005, Trends in cell biology.

[22]  Thierry Mann,et al.  Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. , 2009, Biochimica et biophysica acta.

[23]  Karl Gademann,et al.  The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. , 2010, Bioorganic & medicinal chemistry letters.

[24]  W. Hiddemann,et al.  Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. , 2006, Blood.

[25]  D. Sullivan,et al.  Nuclear export of proteins and drug resistance in cancer. , 2012, Biochemical pharmacology.

[26]  Minoru Yoshida,et al.  CRM1 Is an Export Receptor for Leucine-Rich Nuclear Export Signals , 1997, Cell.

[27]  G. Blobel,et al.  Structure of the nuclear transport complex karyopherin-β2–Ran˙GppNHp , 1999, Nature.

[28]  K. Götze,et al.  Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation , 2008, Haematologica.

[29]  C. Dargemont,et al.  Evidence for a role of CRM1 in signal-mediated nuclear protein export. , 1997, Science.

[30]  S. Mutka,et al.  Identification of nuclear export inhibitors with potent anticancer activity in vivo. , 2009, Cancer research.

[31]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[32]  Karsten Weis,et al.  Exportin 1 (Crm1p) Is an Essential Nuclear Export Factor , 1997, Cell.

[33]  P. Vigneri,et al.  Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase , 2001, Nature Medicine.

[34]  U. Vinkemeier,et al.  Ratjadone and leptomycin B block CRM1‐dependent nuclear export by identical mechanisms , 2004, FEBS letters.

[35]  Minoru Yoshida,et al.  CRM1 is responsible for intracellular transport mediated by the nuclear export signal , 1997, Nature.

[36]  Yoshiyuki Matsuura,et al.  An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1 , 2010, The EMBO journal.

[37]  Karl Gademann,et al.  Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. , 2010, Journal of the American Chemical Society.

[38]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.